Source: bloomberg.com — 05-22-2025
Samsung Biologics shares experienced significant volatility following the announcement of a spin-off plan. The plan involves splitting Samsung Biologics into a contract drug manufacturer and a holding company to oversee its subsidiaries, signaling a broader restructuring within South Korea’s largest conglomerate. Investors are closely monitoring the developments as the company navigates this strategic transformation.
